002462 Cachet Pharmaceutical
WatchlistCachet Pharmaceutical News
[Instant Analysis of BT Financial Report] Jiashitang's 2023 Interim Report: Operating income has increased steadily, net cash flow has increased dramatically
The 2023 interim report of Jiashitang (stock code: 002462) has been published. This article will interpret its financial data from the perspective of a financial analyst. First, let's take a look at Jiashitang's revenue. Revenue for the reporting period was 14,877,717,780.55 yuan, an increase of 17.09% compared to 12,706,434,721.05 yuan for the same period last year. This is mainly due to the increase in revenue from the pharmaceutical wholesale business. However, the net profit attributable to shareholders of listed companies during the reporting period was 155,489,204.07 yuan, compared with 169 in the same period last year.
Jiashitang (002462.SZ): Net profit fell 8.26% in the first half of the year to 155 million yuan
Glonghui, August 30, 丨 Jiashitang (002462.SZ) announced its 2023 semi-annual report. Operating revenue for the reporting period was 14.878 billion yuan, up 17.09% year on year; net profit attributable to shareholders of listed companies was 155 million yuan, down 8.26% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 149 million yuan, down 7.87% year on year; basic earnings per share.
Jiashitang (002462.SZ): Currently, all pharmacy chains are directly managed, and no pharmacy franchise matters have been launched
GLONGHUY July 5: Some investors asked Jiashitang (002462.SZ), “Can the company join the pharmacy chain?” In response, Carshitang said that currently all of the company's pharmacy chains are directly managed, and no pharmacy franchise matters have yet been initiated.
Gashitang (002462.SZ) plans to distribute 3.1 yuan for every 10 shares in 2022, excluding interest on June 30
According to the Zhitong Finance App, Jiashitang (002462.SZ) announced that the company plans to distribute a cash dividend of RMB 3.10 (tax included) for every 10 shares in 2022. The registration date for this equity distribution is: June 29, 2023, and the deduction date is: June 30, 2023.
Gashitang (002462.SZ) released first-quarter results, with net profit of 67.734,200 yuan, a year-on-year decrease of 14.08%
According to the Zhitong Finance App, Jiashitang (002462.SZ) released its report for the first quarter of 2023. The company's operating income during the reporting period was 6.756 billion yuan, an increase of 4.57% over the previous year; net profit attributable to shareholders of listed companies was 67.734 million yuan, a decrease of 14.08% over the previous year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 64,5172 million yuan, a year-on-year decrease of 12.03%; basic earnings per share were 0.23 yuan.
Jiashitang (002462.SZ) announces 2022 results, net profit of 297 million yuan, down 16.09% year-on-year, 3.1 yuan per 10 distribution
According to the Zhitong Finance App, Jiashitang (002462.SZ) disclosed its 2022 annual report. The company achieved annual revenue of 26.220 billion yuan, an increase of 2.32% over the previous year. Net profit attributable to shareholders of listed companies was 297 million yuan, a year-on-year decrease of 16.09%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 284 million yuan, a year-on-year decrease of 17.91%. Basic earnings per share were $1.02 per share. It is proposed to distribute a cash dividend of 3.1 yuan (tax included) for every 10 shares. Up to now, the company's pharmaceutical and device sales business has covered more than terminal mainstream medical institutions
Express News | Pharmaceutical business concept stocks quickly pull up the 4 boards of Jiashitang for 5 days.
The pharmaceutical sector led the rise in the direction of anti-virus.
Gelonghui on December 5, Guizhou lark, Jiashitang, the Yangtze River healthy limit, Shenzhou cells rose by more than 12%, Northeast Pharmaceutical, Hendi Pharmaceutical, Fengyuan Pharmaceutical, and so on are all significantly higher.
Pharmaceutical business concept stocks push up the trading limit of Jiashitang.
On December 2, Gelonghui Drug purchase rose by more than 10%, Jiashitang, Saili Medical limit, gargle civilian, Yixintang, Daga Weikang, Intel Group, Zhejiang Zhenyuan, and so on.
Pharmaceutical commercial stocks pull up collectively, and Jiashitang closes the limit.
On December 1, Gelonghui set off a wave of drug purchases after the optimization of prevention and control measures in many places. Pharmaceutical commercial stocks in the A-share market collectively rose, Jiashitang closed the board in a straight line, gargle civilians, drug Tesco, Dashenlin, Kyushu Tong, and so on. The epidemic prevention and control policy has been optimized in many places throughout the country, and it has been reported that after the epidemic control measures were adjusted in many districts of Guangzhou on November 30, there was a marked increase in the number of customers consulting and purchasing antiviral traditional Chinese medicine. Recently, the sales of this kind of drugs have increased significantly. Xiangxue Pharmaceutical revealed that the company received new orders for 1 million boxes of "Xiangxue antiviral" oral liquid from BABA Pharmacy and Dashenlin yesterday, and the terminal sales of the drug have increased recently than usual.
Express News | The pharmaceutical business sector is pulling up and strengthening.
002462.SZ: third quarter net profit fell 14.17% to 77.6357 million yuan
On October 19, 002462.SZ released its third quarter report for 2022, with operating income of 7.574 billion yuan for the reporting period, an increase of 11.57% over the same period last year. Net profit belonging to shareholders of listed companies was 77.6357 million yuan, down 14.17% from the same period last year. Net profit belonging to shareholders of listed companies excluding non-recurring gains and losses was 75.3174 million yuan, down 14.82% from the same period last year; and basic earnings per share was 0.27 yuan.
002462.SZ 's net profit for the first three quarters was 247 million yuan, down 6.96% from the same period last year.
Zhitong Financial APP News, 002462.SZ released a report for the first three quarters of 2022 that the company realized operating income of 20.281 billion yuan, up 4.81% from the same period last year; realized net profit of 247 million yuan belonging to shareholders of listed companies, down 6.96% from the same period last year; and realized net profit of 237 million yuan after deducting non-recurring profits and losses belonging to shareholders of listed companies, down 8.25% from the same period last year. Basic earnings per share is 0.85 yuan per share.
Express News | The pharmaceutical commercial plate has been pulled up by different movements.
Kashido (002462.SZ): The ban on 41180.805 million restricted shares will be lifted
Glonghui September 27 丨 Jiashitang (002462.SZ) issued an indicative announcement on the listing and circulation of shares issued to specific targets. The number of shares released this time was 41180.85 million shares, accounting for 14.12% of the company's total share capital, which is RMB common stock issued by the company to specific targets in 2018; the number of shareholders whose share restrictions were lifted this time was 1, China Everbright Group Co., Ltd. (“Everbright Group”); the restricted shares were listed on the Shenzhen Stock Exchange on October 10, 2019, for a limited period of 36 months. 2022/10/10
002462.SZ reported a half-year net profit of 169 million yuan, down 3.24% from a year earlier.
Zhitong Financial APP News, 002462.SZ released a half-annual report for 2022, achieving operating income of 12.706 billion yuan, an increase of 1.15% over the same period last year. The net profit belonging to shareholders of listed companies was 169 million yuan, down 3.24% from the same period last year. The net profit after deducting non-recurring gains and losses belonging to shareholders of listed companies was 162 million yuan, down 4.83% from the same period last year. Basic earnings per share is 0.58 yuan per share. The company gives full play to the subjective initiative of the team, faces up to difficulties, pays close attention to implementation, and firmly ensures the company's four main business boards: pharmaceutical sales, medical devices, pharmaceutical equipment logistics and chain retail.
The registration date of 10 equity distributions of Ka Shitang (002462.SZ) 2021 is June 23rd.
On June 15, Gelonghui (002462.SZ) issued an announcement on the implementation of stock rights distribution in 2021, proposing to distribute RMB 3.7 yuan in cash (including tax) for every 10 shares. the registration date of this equity distribution is June 23, 2022, and the de-dividend date is June 24, 2022.
Ka Shitang (002462.SZ) 2021: plan to pay 3.70 yuan per 10 shares to remove rights and interest on June 24th
Zhitong Financial APP, 002462.SZ issued an announcement that the company's annual rights and interests distribution plan for 2021 is to distribute RMB3.70 in cash to all shareholders for every 10 shares. The registration date of this equity distribution is June 23, 2022, and the de-dividend date is June 24, 2022.
002462.SZ reported a net profit of 78.8384 million yuan in the first quarter, down 3.65% from a year earlier.
Zhitong Financial APP News, 002462.SZ released the first quarter of 2022 report, operating income of 6.461 billion yuan, a year-on-year increase of 11.19%. The net profit belonging to shareholders of listed companies was 78.8384 million yuan, down 3.65% from the same period last year. The net profit after deducting non-recurring gains and losses belonging to shareholders of listed companies was 73.3368 million yuan, down 3.83% from the same period last year. Basic earnings per share is 0.27 yuan.
Pharmaceutical commercial stocks continue to pull up the daily limit of Chinese pharmaceutical stocks.
Gronghui rose by the daily limit of Ruikang Pharmaceutical, Jiashitang, Nanjing Pharmaceutical, Chinese Medicine and people's Tongtai on March 31, while Shanghai Pharmaceuticals and Pharmaceutical Tesco rose.